Monique Pond, PhD, Medical Writer and Consultant, at Whitsell Innovations, Inc. will be presenting at the Expedited Review Pathways Conference, Best Practices for Successful Early Launch of Investigational and Unapproved Drugs, being held August 16-17, 2017, at the Embassy Suites by Hilton Alexandria Old Town, in Alexandria, VA.
Dr. Pond will be presenting “Precision Medicine – Best Practices for Leveraging Expedited Approval Programs.” Trial design, companion diagnostics, and patient recruitment considerations will be discussed from the perspective of precision medicine. Recent trends in the use of expedited approval programs among targeted oncology therapies will be highlighted.
“Expedited approval programs can benefit patients by providing them with earlier access to therapies,” says Dr. Pond. “The challenge for life science corporations is determining which expedited program (or programs) best aligns with their unique potential therapy.”
The Expedited Review Pathways Conference will bring together leaders in the pharmaceutical industry to discuss the FDA’s expedited approval programs. This summit is designed to educate potential drug sponsors of novel medications and devices for small populations and emergency health scenarios who are interested in pursuing one or more of FDA’s expedited approval programs.
ABOUT WHITSELL INNOVATIONS, INC.:
WI is a Women’s Business Enterprise National Council (WBENC) certified woman owned full-service medical, scientific, and technical writing company headquartered in Chapel Hill, North Carolina.
Contact: info@whitsellinnovations.com
Website: www.whitsellinnovations.com
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control. Whitsell Innovations, Inc.’s actual results, performance, or achievements could be materially different from those projected by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.
###
